Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA)

Overview of attention for article published in BMC Cancer, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 18 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,957 followers.

New article: Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA) https://t.co/CyOfUbNDeb #breastcancer #oncology https://t.co/dtWX0bMFUY

15 Mar 2022

Reply Repost Favourite

Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA) https://t.co/V95NpyVnGg

15 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.